预防A组链球菌皮肤感染的疫苗经济学论证
该研究估计澳大利亚每年24种A组链球菌(GAS)相关疾病的健康与经济负担,并建模评估不同临床适应症、年龄接种程序及人群的GAS疫苗价值。预防咽喉感染、皮肤感染和蜂窝织炎的疫苗在不同年龄程序中贡献不同比例的价值。结论认为同时预防GAS蜂窝织炎、其他皮肤感染及咽喉感染的疫苗可最大化价值和商业可行性。
要点
- 婴儿程序(每程成本有效疫苗价格260澳元)中咽喉、皮肤、蜂窝织炎感染分别贡献总疫苗价值的30%、33%、28%。
- 儿童程序(289澳元)中上述适应症贡献47%、26%、22%;成人程序(489澳元)贡献2%、15%、74%。
核心结论
- 预防GAS蜂窝织炎及其他皮肤感染并同时预防咽喉感染的疫苗可最大化其价值和商业可行性,其成本有效价格与澳大利亚近期获批并资助的其他疫苗相当。
研究设计与样本
- 研究通过整合行政数据库、全国代表性调查、文献综述、公共报销目录和专家意见估计澳大利亚每年24种GAS相关疾病的健康与经济负担。
- 研究建模了从出生起所有婴儿、5岁起儿童和65岁起成人的GAS终生负担,假设疫苗在10年内将每种GAS疾病减少70%,比较接种与未接种队列的结果差异计算成本有效价值。
主要发现
- 婴儿程序中减少咽喉感染、皮肤感染和蜂窝织炎在非原住民队列中分别贡献总疫苗价值的30%、33%和28%(成本有效疫苗价格每程260澳元)。
- 儿童程序中上述适应症分别贡献47%、26%和22%(每程289澳元);成人程序中分别贡献2%、15%和74%(每程489澳元)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Group A streptococcus (GAS) causes an exceptionally diverse range of diseases, raising questions about the optimal product characteristics of a commercially viable vaccine. The objectives of this study were to (1) estimate the current health and economic burdens caused by 24 diseases attributable to GAS each year in Australia and (2) use these estimates to explore the value of a GAS vaccine for different clinical indications, age schedules, and population groups. METHODS: For objective 1, we estimated the population heath and economic burdens by synthesising data from administrative databases, nationally representative surveys, literature reviews, public reimbursement schedules, and expert opinion. For objective 2, we modelled the prospective lifetime burden of GAS for all infants from birth, for children from 5 years of age, and for adults from 65 years of age. A vaccine was assumed to reduce each GAS disease by 70% for a period of 10 years, and the difference in outcomes between vaccinated and non-vaccinated cohorts were used to calculate the cost-effective value of vaccination. RESULTS: The annual health and economic burdens of GAS diseases totalled 23,528 disability-adjusted life years and AU$185.1 million in healthcare costs respectively; approximately half of each measure was due to cellulitis, followed by other skin infections and throat infections. Reducing the incidence of throat infections, skin infections, and cellulitis in non-Indigenous cohorts resulted in 30%, 33%, and 28% of the total vaccine value for an infant schedule (cost-effective vaccine price AU$260 per course); 47%, 26%, and 22% of the value for a child schedule (AU$289); and 2%, 15% and 74% for an adult schedule (AU$489). CONCLUSIONS: A vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability, with a cost-effective price in line with other recently-licensed and funded vaccines in Australia.
引用
- Cannon JW, Jack S, Wu Y, et al. An economic case for a vaccine to prevent group A streptococcus skin infections. Vaccine. 2018. PMID: 30340879. doi:10.1016/j.vaccine.2018.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。